玻璃体内注射雷珠单抗治疗成人型中心性黄斑卵黄样营养不良合并的3型脉络膜新生血管。
Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy.
作者信息
Querques G, Querques L, Leveziel N, Bandello F, Souied E H
机构信息
Department of Ophthalmology, University Paris XII, Centre Hospitalier Intercommunal de Créteil, 40 Avenue de Verdun, 94000 Créteil, France.
出版信息
J Fr Ophtalmol. 2013 Jan;36(1):e1-4. doi: 10.1016/j.jfo.2012.04.013. Epub 2012 Dec 4.
PURPOSE
To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV).
METHODS
A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5mg were administered intravitreally without complications.
RESULTS
After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed.
CONCLUSIONS
Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.
目的
描述玻璃体内注射雷珠单抗治疗一名成年发病的中心性黄斑卵黄样营养不良（AOFVD）合并3型脉络膜新生血管（CNV）患者的结果。
方法
一名78岁被诊断为AOFVD的男性因左眼视力下降（20/80）前来我院就诊。经过包括荧光素血管造影、吲哚菁绿血管造影和光谱域光学相干断层扫描在内的全面眼科检查，该患者被诊断为3型CNV。每月3次玻璃体内注射0.05 ml/0.5mg雷珠单抗，未出现并发症。
结果
首次注射后，左眼视力提高（20/64），荧光素血管造影、吲哚菁绿血管造影和光学相干断层扫描观察到3型CNV消退。最后一次注射雷珠单抗6个月后，观察到渗出性视网膜病变大致完全消退。
结论
3型CNV可能与AOFVD相关。在这种特殊情况下，玻璃体内注射雷珠单抗可能是一种可行的治疗选择。
Zotero 插件